Skip to main content
Gulf Pharmaceutical Industries logo

Gulf Pharmaceutical Industries — Investor Relations & Filings

Ticker · JULPHAR ISIN · AEG000201018 Abu Dhabi Securities Exchange Manufacturing
Open in API
Filings indexed 360 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country AE United Arab Emirates
Listing Abu Dhabi Securities Exchange JULPHAR

About Gulf Pharmaceutical Industries

https://www.Julphar.net

Gulf Pharmaceutical Industries (Julphar) is a prominent pharmaceutical manufacturer and distributor. The company specializes in producing a diverse portfolio of medicines, vaccines, and consumer healthcare products, addressing a broad spectrum of health conditions. Julphar is recognized as one of the largest generic pharmaceutical manufacturers in the Middle East and North Africa, and a leading global producer of insulin. Utilizing internationally accredited, state-of-the-art facilities, it manufactures over one million medicine boxes daily, distributing products to more than 40 countries. The company's operations emphasize high quality and safety standards in its comprehensive manufacturing capabilities.

Recent filings

Filing Released Lang Actions
إعادة التداول على أسهم شركة الخليج للصناعات الدوائية JULPHAR في 15 مايو 2026
Interim / Quarterly Report Classification · 95% confidence The document contains the full unaudited consolidated interim financial statements (statement of profit or loss, statement of financial position, cash flow, changes in equity, notes) for the three months ended 31 March 2026, along with an independent review report under IFRS IAS 34. It is a comprehensive interim/quarterly financial report, not merely an announcement or summary. Therefore, it qualifies as an Interim / Quarterly Report. Q1 2026
2026-05-15 Arabic
Resume trading on Gulf Pharmaceutical Industries-JULPHAR shares on 15 May 2026
Interim / Quarterly Report Classification · 90% confidence The document is titled “Interim Condensed Consolidated Financial Statements” for the three‐month period ended 31 March 2026, includes detailed interim profit or loss, comprehensive income, financial position, cash flows, changes in equity, notes, and an auditors’ review report under IAS 34. This aligns exactly with a quarterly/interim report rather than a full annual report or mere announcement. Q1 2026
2026-05-15 English
شركة الخليج للصناعات الدوائية النتائج المالية للفترة المنتهية في 31 مارس,2026
Interim / Quarterly Report Classification · 97% confidence The document presents the actual interim condensed consolidated financial statements for the three months ended March 31, 2026, including an auditor’s review report, income statement, statement of comprehensive income, statement of financial position, statement of changes in equity, statement of cash flows, and detailed notes. It is not merely an announcement or summary but the full interim financial report covering a quarter, fitting the definition of an Interim / Quarterly Report. Q1 2026
2026-05-13 Arabic
Gulf Pharmaceutical Industries Financial Results for the Period Ended March 31,2026
Interim / Quarterly Report Classification · 95% confidence The document is titled "INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) 31 MARCH 2026" for Gulf Pharmaceutical Industries (JULPHAR CO Public JSC). It includes an independent auditor’s review under IAS 34, detailed interim statements of profit or loss, comprehensive income, financial position, changes in equity, cash flows, and accompanying notes for the three‐month period. This is a full interim/quarterly financial report, not merely an earnings press release or announcement. Therefore, it falls squarely into the Interim/Quarterly Report category. Q1 2026
2026-05-13 English
شركة الخليج للصناعات الدوائية تقرير مناقشة وتحليل الإدارة عن الفترة المنتهية في 31 مارس,2026
Management Reports Classification · 92% confidence The document is titled “تقرير مناقشة وتحليل مجلس إدارة الشركة المساهمة المدرجة” (Board of Directors’ discussion and analysis) covering the company’s Q1 2026 performance, including revenue breakdown, profit metrics, cash flows, strategic initiatives, and future outlook. It provides management’s detailed explanation of financial results and business trends for the quarter, without full statutory financial statements. This matches the Management Reports (MD&A) category.
2026-05-13 Arabic
Gulf Pharmaceutical Industries Management Discussion and Analysis Report for the Period Ended March 31,2026
Management Reports Classification · 90% confidence The document is a standalone “Discussion report and analysis of the board of directors” covering Q1 2026, containing detailed commentary on revenue, margins, EBITDA, cash flows, financial position, operational performance, market outlook, and future plans. It is a management discussion and analysis piece, not merely an announcement, transcript, or full annual report. Therefore it best fits the Management Reports (MDA) category.
2026-05-13 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.